Association between the rs28366003 (MT2A -5A/G) single nucleotide polymorphism and human diseases
| Authors and year of publication (reference No.) | Ethnicity | n | Study participants | Sample type | Findings |
|---|---|---|---|---|---|
| Shokrzadeh et al., 2019 (101) | Iranian | 95 | Men and women with gastric cancer | Leukocytes | SNP MT2A -5A/G increase the risk of gastric |
| 90 | Control healthy men and women | adenocarcinoma | |||
| Bialkowska et al., 2018 (88) | 197 | Men with prostate cancer | Whole blood | No association was found between SNP MT2A -5A/ | |
| 197 | Control men without prostate cancer | G and prostate cancer | |||
| Liu et al., 2017 (100) | Chinese | 459 | Women with breast cancer | Whole blood | SNP MT2A -5A/G was associated with different |
| 549 | Control healthy women | types of breast cancer | |||
| 130 | Men and women with AMD | AG genotype subjects had 5.5-fold higher risk for | |||
| Garcia et al., 2017 (97) | Spanish | 96 | Control healthy men and women | Whole blood | AMD; G allele was associated with dry form of AMD |
| Raudenska et al., 2017 (103) | 70 | Men and women with type 2 diabetes mellitus | No association was found between SNP MT2A -5A/ | ||
| 80 | Control healthy men and women | G and type 2 diabetes mellitus | |||
| 165 | Men and women with DM | ||||
| Hattori et al., 2016 (95) | Japanese | 417 | Men and women with CKD | Serum | GG genotype associated with CKD and AG genotype with DM; no association of MT2A -5A/G and HT |
| 2192 | Healthy men and women | ||||
| 130 | Men and women with SIP | SNP MT2A -5A/G was related to SIP (Schneiderian | |||
| Starska et al., 2015 (80) | 418 | Control men and women without head or neck tumour | papilloma); G allele increased 7.7-fold occurrence of SIP (Schneiderian papilloma); SNP MT2A -5A/G was associated with SIP phenotype | ||
| Polish | 117 | Men and women with SIP | Tissue of nasal cavities or | Heterozygotes vs. homozygotes had increased risk | |
| Starska et al., 2015 (84) | 132 | Control men and women with normal sinonasal mucosa | paranasal sinuses | of SIP | |
| 323 | Men and women with laryngeal cancer | AG genotype subjects had 1.6-fold higher risk for | |||
| Starska et al., 2014 (81) | 418 | Control healthy men and women | laryngeal cancer development; Association between SNP MT2A -5A/G and tumour aggressiveness | ||
| Kizeslak et al., 2014 (82) | 534 | Women with ductal breast cancer | SNP MT2A -5A/G was associated with ductal breast | ||
| Polish | 556 | Control healthy women | Whole blood | cancer | |
| Kiześlak et al., 2013 (86) | Polish | 412 | Men with prostate cancer | AG genotype had higher risk for occurrence of | |
| 67 | Control men without prostate cancer | prostate cancer | |||
| Forma et al., 2012 (87) | Polish | 358 | Men with prostate cancer | Prostate tissue | SNP MT2A -5A/G was associated with prostate |
| 406 | Control men without prostate cancer | cancer and Gleason score | |||
| Kayaalty et al., 2011 (92) | Turkish | 354 | Healthy men and women | Whole blood | SNPMT24 -5A/G was associated with longevity |
| Hayashi et al., 2006 (96) | Japanese | 37 | Patients with SALS | Whole blood | No association between SNP MT2A -5A/G and |
| 206 | Control healthy men and women | SALS and progression rate | |||
Association between the rs28366003 (MT2A -5A/G) single nucleotide polymorphism and element concentrations in humans
| Authors and year of publication (reference No.) | MT2A genotype | |||||||
|---|---|---|---|---|---|---|---|---|
| Ethnicity | n | Study participants | Sample type | AA | AG | GG | Findings | |
| As concentrations (μg/g creatine) | ||||||||
| Stajnko et al., 2019 (99) | Croatian | 136 | Pregnant women | Urine | 3.07* | 4.58*.§ | No differences between genotypes | |
| Gonzalez-et al., 2018 Martinez, (102) | Colombian | 101 | Men and women | Urine | (Not available) | No and association SNP MT2between A -5A/G As | ||
| Cd concentrations (μg/L* or μg/kg) | ||||||||
| Maternal blood | 0.87±0.99* | 0.73±0.60*,§ | ||||||
| Sekovanić et al., | Croatian | 268 | Mother-newborn pairs | Cord blood | 0.06±0.03* | 0.05±0.03*,§ | No difference in either | |
| 2018(4) | Placenta | 10.1±5.1 | 8.80±3.70§ | sample between genotypes | ||||
| Hattori et al., 2016 (95) | Japanese | 2774 | Men and women | Serum | (Graphical illustration: Cd = 0.001*) | No differences between genotypes | ||
| Adams et al, 2015 (104) | US | 321 | Men and women | Urine | (Graphical illustration) | ↓Cd in urine of G allele carriers | ||
| Starska et al., 2015 (84) | Polish | 117 | Men and women with SIP | 116±79 | 376±126 | 393 | AG vs. AA genotype ↑Cd in SIP samples; no association between Cd and SNP MI2A -5A/G in control samples | |
| 132 | Control men and women with normal sinonasal mucosa | Tissue of nasal or paranasal sinuses (dry) | 62.2±41.2 | 96.2±57.1 | - | |||
| 323 | Men and women with SCC | 198±87 | 369±128 | 509±57 | AG vs. AA genotype ↑Cd in | |||
| Starska et al., 2014 (85) | Polish | 116 | Control men and women with normal laryngeal mucosa | Tissue of laryngeal mucosa (dry) | 87.2±32.2 | 113±26 | 117 | both sample types; GG vs. AA and AG vs. GG genotype ↑Cd in SCC samples |
| Krzeslak et al., 2013 (86) | Polish | 412 | Men with prostate cancer | Prostate tissue (dry) | 720±330 | 970±460 | 1090±220 | AG vs. AA genotype ↑Cd in both sample types; GG vs. AA genotype ↑Cd in prostate cancer samples |
| Tekin et al, 2012 | Maternal blood | 1.60±0.94* | 2.54±2.72* | AG vs. AA genotype |Cd in | ||||
| Turkish | 95 | Mother-newborn pairs | Cord blood | 0.95±0.32* | 0.98±0.28* | maternal blood and ↓Cd in | ||
| Placenta | 20.8±19.7 | 8.65±6.70 | placenta | |||||
| Kayaalti et al, 2011 (91) | Turkish | 616 | Men and women | Whole blood | 1.60±1.44* | 2.09±1.85* | 5.98±4.38* | G allele carriers ↑Cd |
| Kayaalti et al, 2010 (94) | Turkish | 114 | Men and women | Kidney samples (dry) | 87.7±62.9† | 151±60† | 153f | ↑Cd in G allele carriers |
| Pb concentrations (μg/L*or μg/kg) | ||||||||
| Maternal blood | 13.7±6.6* | 12.0±3.6*,§ | ||||||
| Sekovanić et al., 2018(4) | Croatian | 268 | Mother-newborn pairs | Cord blood | 8.3±5.5* | 7.1±4.0*-s | No difference in either sample between genotypes | |
| Placenta | 6.9±4.9 | 5.5±2.8§ | ||||||
| Yang et al, 2017 (105) | Thai | 677 | Men and women | Whole blood | 122±122* | 105±113* | - | No differences between genotype |
| Maternal blood | 3.53±1.43* | 5.13±2.79* | - | |||||
| Tekin et al, 2012 (901 | Turkish | 91 | Mother-newborn pairs | Cord blood | 2.42±1.00* | 2.94±1.49* | - | AG vs. AA genotype ↑ Pb in maternal blood |
| Placenta | 7.79±2.55 | 9.75±4.14 | - | |||||
| Krzeslaketal, 2013 (86) | 412 | Men with prostate cancer | 3.11±1.27† | 4.66±1.82† | 5.11±2.52† | GG vs. AA genotype ↑Pb in | ||
| Polish | 67 | Control men without prostate cancer | Prostate tissue (dry) | 1.67±0.61f | 1.72±0.67f | - | prostate cancer | |
| Kayaalti et al, 2011 (91) | Turkish | 616 | Men and women | Plasma | 30.1±13.9* | 32.9±14.9* | 50.4±11.5* | G allele carriers ↑Pb |
| Hg concentrations (μg/L*or μg/kg) | ||||||||
| Maternal blood | 13.7±6.6* | 12.0±3.6*s | ||||||
| Sekovanić et al., 2018(4) | Croatian | 268 | Mother-newborn pairs | Cord blood | 8.3±5.5* | 7.1±4.0*,§ | No difference in either sample between genotypes | |
| Placenta | 6.9±4.9 | 5.5±2.8§ | ||||||
| Wang et al., 2012 | TTC | 239 | Men and women | Urine | 1.03* | 0.76* | 0.34* | No difference between |
| (106) | 247 | Men and women | Hair | 440 | 390 | 430 | genotypes | |
| Fe concentrations (mg/L*or mg kg-1) | ||||||||
| Maternal blood | 422±61* | 418±56*,§ | ||||||
| Sekovanić et al., 2018(4) | Croatian | 268 | Mother-newborn pairs | Cord blood | 552±61* | 539±57*,§ | G allele carriers (AG+GG) vs. AA genotype ↓Fe in placenta | |
| Placenta | 83±22 | 74±18§ | ||||||
| Maternal blood | 343±89* | 373±103* | - | |||||
| Tekin et al, 2012 | Turkish | 95 | Mother-newborn pairs | Cord blood | 271±130* | 456±214* | - | AG vs. AA genotype ↑Fe in cord blood |
| Placenta | 527±194 | 624±162 | - | |||||
| Zn concentrations (mg/L*or mg kg-1) | ||||||||
| Maternal blood | 5.58±0.92* | 5.51±0.82*,§ | ||||||
| Sekovanić et al., 2018(4) | Croatian | 268 | Mother-newborn pairs | Cord blood | 2.78±0.46* | 2.58±0.53*,§ | No difference in either sample between genotypes | |
| Placenta | 13.7±3.0 | 13.4±1.8§ | ||||||
| 70 | Men and women with diabetics | (Graphical illustration: Zn= 3* in AG vs. ~ 7.5* in AA) | AG vs. AA genotype ↓Zn in blood in diabetics | |||||
| Raudenskaet al., 2017(103) | Czech | 80 | Control healthy men and women | Whole blood | (Graphical illustration: Zn= 5* in AG vs. ~ 6* in AA) | no association between Zn and SNP MT2A -5A/G in the control samples | ||
| Hattori et al., 2016 (95) | Japanese | 2774 | Men and women | Serum | (Graphical illustration: Zn = 0.850*) | No differences between genotypes | ||
| Adams et al, 2015 (104) | US | 321 | Men and women | Urine | (Graphical illustration) | ↓Zn in urine of G allele carriers | ||
| 117 | Men and women with SIP | Tissue of nasal cavities or paranasal sinuses (dry) | 52.2±41.2 | 127±76 | 136 | AG vs. AA genotype ↑Zn in SIP tissue samples; | ||
| Starska et al., 2015 (84) | Polish | 132 | Control men and women with normal sinonasal mucosa | 199±44 | 204±52 | - | No association between Zn and SNPMT24 -5A/G in control samples | |
| 323 | Men and women with SCC | 86.4±38.1 | 184±57 | 194±74 | AG vs. AA genotype ↑Zn in | |||
| Starska et al., 2014 (85) | Polish | 116 | Control men and women with normal laryngeal mucosa | Tissue of laryngeal mucosa | 97.6±30.0 | 133±27 | 129 | both sample types; GG vs. AA genotype ↑Zn in SCC samples |
| Krzeslak et al., 2013 (86) | 412 | Men with prostate cancer | 135±48 | 239±80 | 243.7±64.4 | AG vs. AA genotype ↑Zn in both sample types; GG vs. | ||
| Polish | 67 | Control men without prostate cancer | Prostate tissue (dry) | 485±119 | 927±317 | AA genotype |Zn in cancer samples | ||
| Maternal blood | 4.33±1.13* | 4.82±1.44* | - | |||||
| Tekin et al, 2012 (89) | Turkish | 95 | Mother- newborn pairs | Cord blood | 1.32±0.55* | 1.48±0.53* | - | No difference between genotypes |
| Placenta | 50.5±10.1 | 46.1±7 | - | |||||
| Kayaaltietal,2011(91) | Turkish | 616 | Men and women | Plasma | 1.01±0.48* | 0.84±0.50* | 0.39±0.33* | G allele carriers ↓Zn |
| Kayaalti et al., 2010 (94) | Turkish | 114 | Men and women | Kidney tissue (dry) | 180.2±84.6 | 192±115 | 142 | No difference between genotypes |
| Cu concentrations (mg/L*or mg kg-1) | ||||||||
| Maternal blood | 1.52±0.30* | 1.53±0.09*§ | ||||||
| Sekovanić et al., 2018(4) | Croatian | 268 | Mother-newborn pairs | Cord blood | 0.59±0.09* | 0.58± 0.12*,§ | No difference in either sample between genotypes | |
| Placenta | 0.78±0.18 | 0.74± 0.08§ | ||||||
| Adams et al, 2015 (104) | US | 321 | Men and women | Urine | ( | Graphical illustration) | ↓Cu in urine of G allele carriers | |
| 117 | Men and women with SIP | Tissue of nasal cavities or paranasal sinuses (dry) | 24.2±13.6 | 27.1±11.6 | 26.2 | No differences between | ||
| Starska et al., 2015 (84) | Polish | 132 | Control men and women with normal sinonasal mucosa | 11.0±2.98 | 17.2±5.2 | - | genotypes in SIP tissue samples; AG vs. AA genotype ↑Cu in control samples | |
| 323 | Men and women with SCC | 14.4±7.83 | 26.6±12.5 | 29.7±0.72 | AG vs. AA genotype |Cu in | |||
| Starska et al., 2014 (85) | Polish | 116 | Control men and women with normal laryngeal mucosa | Tissue of laryngeal mucosa | 9.85±4.10 | 12.7±3.56 | 11.5 | both sample types; GG vs. AA genotype |Cu in SCC samples |
| 412 | Men with prostate cancer | 10.3±4.2 | 21.1±9.6 | 25.6±5.8 | AG vs. AA genotype | |||
| Krzeslak et al., 2013 (86) | Polish | 67 | Control men without prostate cancer | Prostate tissue (dry) | 2.9±1.3 | 7.6±2.9 | - | ↑Cu in both sample types; GG vs. AA genotype ↑ Cu in cancer samples |
| Maternal blood | 1.67±0.34* | 1.84±0.50* | - | |||||
| Tekin (89) et al, 2012 | Turkish | 95 | Mother-newborn pairs | Cord blood | 0.69±0.25* | 0.69±0.28* | - | No difference genotypes between |
| Placenta | 5.90±2.59 | 6.63±1.73 | - | |||||
| Kayaalti et al., 2011 (91) | Turkish | 616 | Men and women | Plasma | 1.04±0.44* | 1.02±0.52* | 0.91±0.37* | No difference genotypes between |
| Kayaalti et al., 2010(94) | Turkish | 114 | Men and women | Kidney tissue (dry) | 17.2±16.9 | 15.3±10.6 | 31.9 | No difference genotypes between |
Genotype frequencies of the rs10636 (MT2A +838G/C) single nucleotide polymorphism in humans
| Authors and year of publication (reference No.) | Ethnicity | n | Study participants | Genotype frequencies (%) | ||
|---|---|---|---|---|---|---|
| GG | GC | CC | ||||
| Yang et al., 2017 (105) | Thai | 677 | Men and women | 52.4 | 41.6 | 6.0 |
| Liu et al., 2017 (100) | Chinese | 459 | Women with breast cancer | 52.5 | 37.5 | 11.8 |
| 549 | Control healthy women | 52.8 | 40.8 | 6.4 | ||
| García et al., 2017 | Spanish | 130 | Men and women with AMD | 56.9 | 36.9 | 6.2 |
| (97) | 96 | Control healthy men and women | 67.7 | 27.1 | 5.2 | |
| Fernandes (119) et al., 2016 | Brazilian | 221 | Workers in car battery factories | 62.0 | 32.0 | 6.0 |
| Adams et al., 2015 | US | 170 | Premenopausal women | 54.0 | 42.0 | 4.0 |
| (104) | 151 | Men and women | 62.0 | 34.0 | 4.0 | |
| 130 | Men and women with SIP | 44.6 | 43.1 | 12.3 | ||
| Starska et al., 2015 (80) | Polish | 418 | Control men and women without head and neck tumours | 50.9 | 41.2 | 7.9 |
| Starska et al., 2014 | Polish | 323 | Men and women with laryngeal cancer | 45.8 | 46.1 | 8.1 |
| (81) | 418 | Control volunteers (men and women) | 50.9 | 41.2 | 7.9 | |
| Yang et al., 2014 | Chinese | 287 | Men and women with CHD | 46.0 | 45.3 | 8.7 |
| (117) | 226 | Control healthy men and women | 57.1 | 36.7 | 6.2 | |
| Krześlak et al., 2014 | 534 | Women with breast cancer | 57.1 | 38.4 | 4.5 | |
| (82) | Polish | 556 | Control healthy women | 50.3 | 45.5 | 4.2 |
| Woods et al., 2013 | 163 | Boys average age 10 years | 61.3 | 30.7 | 8.0 | |
| (116) | Portuguese | 167 | Girls average age 10 years | 59.9 | 33.5 | 6.6 |
| Chen et al., 2012 (118) | Chinese | 465 | Men and women | 52.3 | 39.5 | 8.2 |
| Wang et al., 2012 (106) | US | 464 | Men and women | 54.1 | 36.8 | 9.1 |
| Forma et al., 2012 | Polish | 358 | Men with prostate cancer | 48.9 | 43.3 | 7.8 |
| (87) | 406 | Control men without prostate cancer | 52.0 | 40.0 | 8.0 | |
| Gundacker 2009 (120) et al., | Austrian | 180 | Men and women | 58.4 | 33.3 | 8.3 |
| Yang et al., 2008 | Chinese | 182 | Men and women with DM | 46.7 | 42.9 | 10.4 |
| (115) | 196 | Control volunteers (men and women) | 42.9 | 47.4 | 9.70 | |
| 100 | CS patients | 73.0 | 22.0 | 5.0 | ||
| Giacconi et al., 2007 (113) | Italian | 188 | CS patients without cerebrovascular episodes | 66.0 | 30.0 | 4.0 |
| 218 | Control elderly volunteers | 56.0 | 37.0 | 7.0 | ||
Association between the rs1610216 SNP (MT2A -209A/G) single nucleotide polymorphism and human diseases
| Authors and year of publication (reference No.) | Ethnicity | n | Study participants | Sample type | Findings |
|---|---|---|---|---|---|
| 130 | Men and women with SIP | Tissue of nasal cavities or | No association between SNP MT2A | ||
| Starska et al., 2015 (80) | Polish | 418 | Control men and women without head and neck tumours | paranasal sinuses | -209A/G and SIP |
| 323 | Men and women with laryngeal cancer | Tissue of squamous cell | No association between SNPMT24 | ||
| Starska et al., 2014(81) | 418 | Control volunteers (men and women) | laryngeal cancer | -209A/G and development of laryngeal cancer | |
| Krzeslak et al., 2014(82) | Polish | 534 | Women with breast cancer | Whole blood | No associations between SNP MT2A |
| 556 | Control healthy women | -209A/G and breast cancer | |||
| Forma et al, 2012 (87) | Polish | 358 | Men with prostate cancer | Whole blood | No association between SNPMT24 |
| 406 | Control men without prostate cancer | -209 A/G and prostate cancer | |||
| 142 | Patients with CAD | Positive association between G allele carriers | |||
| Kozarova et al., 2012 | Bulgarian | 101 | Patients with DM | Leukocytes | and DM; |
| (114) | 61 | Control healthy volunteers | No association between SNF MT2A -209 A/G and CAD | ||
| 100 | CS patients | ||||
| Giacconi et al., 2007 (113) | Italian | 188 | CS patients without cerebrovascular episodes | Blood | No association between SNPMT24 -209 A/G and CS or cerebrovascular episodes |
| 218 | Control elderly volunteers | ||||
| Giacconi et al., 2005 (112) | Italian | 91 | Men and women with carotid stenosis | Whole blood | No association between SNF MT2A -209A/G and hypertension; higher risk of |
| 188 | Control elderly men and women | ischaemic cardiomyopathy and hyperglycaemia in AA genotype subjects | |||
Genotype frequencies of the rs1610216 (MT2A −209A/G) single nucleotide polymorphism in humans
| Authors and year of publication (reference No.) | Genotype frequencies (%) | |||||
|---|---|---|---|---|---|---|
| Ethnicity | n | Study population | AA | AG | GG | |
| Starska et al., 2015 | 130 | Men and women with SIP | 73.8 | 25.4 | 0.8 | |
| (80) | Polish | 418 | Control men and women without head and neck tumours | 73.9 | 25.3 | 0.8 |
| Starska et al., 2014 | Polish | 323 | Men and women with laryngeal cancer | 73.4 | 26.0 | 0.6 |
| (81) | 418 | Control healthy men and women | 73.9 | 25.3 | 0.8 | |
| Krześlak et al., | Polish | 534 | Women with breast cancer | 76.4 | 23.4 | 0.2 |
| 2014 (82) | 556 | Control healthy women | 72.3 | 27.5 | 0.2 | |
| Forma et al., 2012 | Polish | 358 | Men with prostate cancer | 71.8 | 27.6 | 0.6 |
| (87) | 406 | Control men without prostate cancer | 72.0 | 27.8 | 0.2 | |
| 142 | Patients with CAD | 89.2 | 9.4 | 1.4 | ||
| Kozarova 2012 (114et ) al., | Bulgarian | 101 | Patients with DM | 69.7 | 28.3 | 2.0 |
| 61 | Control healthy volunteers | 90.5 | 0.0 | 9.5 | ||
| 100 | CS patients | 75.0 | 24.0 | 1.0 | ||
| Giacconi et al., 2007 (113) | Italian | 188 | CS patients without cerebrovascular episodes | 73.0 | 25.0 | 2.0 |
| 218 | Control elderly volunteers | 71.0 | 26.0 | 3.0 | ||
| Giacconi et al., | Italian | 91 | Men and women with carotid stenosis | 86.0 | 14.0 | 0.0 |
| 2005 (112) | 188 | Control elderly men and women | 70.2 | 26.1 | 3.7 | |
Association between the rs1610216 (MT2A -209A/G) single nucleotide polymorphism and element concentrations in humans
| Authors and year of publication (reference No.) | MT2A genotype | |||||||
|---|---|---|---|---|---|---|---|---|
| Ethnicity | n | Study participants | Sample type | AA | AG | GG | Findings | |
| Zn concentrations (mg/L) | ||||||||
| Giacconi et al., 2005 (112) | Italian | 91 | Patients: elderly men and women with type 2 diabetes and carotid stenosis | Plasma | 0.77±0.15 | 0.88±0.18.§ | ↓Zn in AA vs. AG+GG in patients; in AA genotype subjects ↓Zn in patients 188 Control: healthy elderly men and vs. control | |
| 188 | Control: healthy elderly men and vs. control women | 0.87±0.25 | 0.88±0.15.§ | |||||
Association between the rs10636 (MT2A +838G/C) single nucleotide polymorphism and human diseases
| Authors and year of publication (reference No.) | Ethnicity | n | Study participants | Sample type | Findings |
|---|---|---|---|---|---|
| Liu et al., 2017 (100) | Chinese | 459 | Women with breast cancer | Whole blood | SNPMT2A +838 G/C was associated with breast cancer |
| 549 | Control healthy women | ||||
| Garcia et al., 2017 (97) | Spanish | 130 | Men and women with AMD | Whole blood | No association between SNPMT2A +838 G/C and AMD |
| 96 | Control healthy men and women | ||||
| Starska et al., 2015 (80) | Polish | 130 | Men and women with SIP | Tissue of nasal cavities or paranasal sinuses | No association between SNP MT2A +838G/C and SIP |
| 418 | Control men and women without head and neck tumours | ||||
| Starska et al., 2014 (81) | Polish | 323 | Men and women with laryngeal cancer | Tissue of squamous cell | No association between SNP MT2A +838G/C |
| 418 | Control heathy men and women | laryngeal cancer | and development of laryngeal cancer | ||
| Yang et al., 2014 (117) | Chinese | 287 | Men and women with CHD | Blood leukocytes | SNPMT2A +838G/C was associated with CHD |
| 226 | Control healthy men and women | ||||
| Krzeslak et al., 2014 (82) | Polish | 534 | Women with breast cancer | Whole blood | No associations between SNPMT24 +838G/C and breast cancer |
| 556 | Control healthy women | ||||
| Yang et al., 2008 (115) | Chinese | 397 | Men and women with DM | Whole blood | SNPMT24 +838G/C was associated with higher risk for hyperlipidemia and incidence of DM with neuropathy |
| 454 | Control men and women | ||||
| Giacconi et al., 2007 (113) | Italian | 100 | CS patients | Blood | SNPMT24 +838G/C promote the progression of carotid artery disease to CS |
| 188 | CS patients without cerebrovascular episodes | ||||
| 218 | Control elderly volunteers | ||||
Genotype frequencies of the rs28366003 (MT2A −5A/G) single nucleotide polymorphism in humans
| Authors and year of publication (reference No.) | Genotype frequencies (%) | |||||
|---|---|---|---|---|---|---|
| Ethnicity | n | Study participants | AA | AG | GG | |
| Stajnko et al., 2019 (99) | Croatian | 136 | Pregnant women | 93.0# | 7.0$ | |
| Slovenian | 176 | Non-pregnant women | 95.0# | 5.0$ | ||
| Shokrzadeh et al., 2019 (101) | Iranian | 95 | Men and women with gastric cancer | 46.4 | 41.0 | 12.6 |
| 90 | Control healthy men and women | 57.8 | 37.8 | 4.4 | ||
| Sekovanić et al., 2018 (4) | Croatian | 268 | Mother-newborn pairs | 94.0 | 6.0 | § |
| González-al., 2018 (Martínez 102) et | Colombian | 101 | Men and women | 53.4 | 43.6 | 3.0 |
| Białkowska et al., 2018 | Polish | 197 | Men with prostate cancer | 90.9 | 9.1§ | |
| (88) | 197 | Control men without prostate cancer | 89.3 | 10.7§ | ||
| Yang et al., 2017 (105) | Thai | 677 | Men and women | 79.5 | 20.5 | 0.0 |
| Liu et al., 2017 (100) | Chinese | 459 | Women with breast cancer (various types) | 82.3 | 15.3 | 2.4 |
| 549 | Control healthy women | 92.5 | 7.5 | 0.0 | ||
| 130 | Men and women with AMD | 88.5 | 11.5 | 0.0 | ||
| García et al., 2017 (97) | Spanish | 96 | Control healthy men and women | 97.9 | 2.1 | 0.0 |
| Raudenska et al., 2017 (103) | 70 | Men and women with type 2 diabetes mellitus | 88.6 | 8.6 | 0.0 | |
| Czech | 80 | Control healthy men and women | 86.3 | 13.7 | 0.0 | |
| Hattori et al., 2016 (95) | Japanese | 2774 | Men and women | 81.8 | 17.4 | 0.8 |
| Adams et al., 2015 (104) | US | 170 | Premenopausal women | 88.0 | 12.0 | 0.0 |
| 151 | Men and women | 84.0 | 15.0 | 1.0 | ||
| 130 | Men and women with SIP | 75.4 | 23.8 | 0.8 | ||
| Starska et al., 2015 (80) | Polish | 418 | Control men and women without head or neck tumour | 95.5 | 4.1 | 0.0 |
| 117 | Men and women with SIP | 76.1 | 23.1 | 0.8 | ||
| Starska et al., 2015 (84) | Polish | 132 | Control men and women with normal sinonasal mucosa | 87.9 | 12.1 | 0.0 |
| 323 | Men and women with SCC | 89.2 | 9.9 | 0.9 | ||
| Starska et al., 2014 (85) | Polish | 116 | Control men and women with normal laryngeal mucosa | 84.5 | 14.6 | 0.9 |
| 323 | Men and women with laryngeal cancer | 89.2 | 9.9 | 0.9 | ||
| Starska et al., 2014 (81) | Polish | 418 | Control healthy men and women | 84.0 | 16.0 | 0.0 |
| Krześlak et al., 2014 (82) | 534 | Women with ductal breast cancer | 87.1 | 12.3 | 0.6 | |
| Polish | 556 | Control healthy women | 92.8 | 7.2 | 0.0 | |
| Krześlak et al., 2013 (86) | 412 | Men with prostate cancer | 76.0 | 21.1 | 2.9 | |
| Polish | 67 | Control men without prostate cancer | 88.0 | 12.0 | 0.0 | |
| Wang et al., 2012 (106) | US | 239 | Men and women | 89.1 | 10.1 | 0.8 |
| 358 | Men with prostate cancer | 76.8 | 20.9 | 2.3 | ||
| Forma et al., 2012 (87) | Polish | 406 | Control men without prostate cancer | 88.9 | 10.6 | 0.5 |
| Tekin et al., 2012 (89) | Turkish | 95 | Mother-newborn pairs | 87.4 | 12.6 | 0.0 |
| Tekin et al., 2012 (90) | Turkish | 91 | Mother-newborn pairs | 86.8 | 13.2 | 0.0 |
| Kayaalti et al., 2011 (91) | Turkish | 616 | Men and women | 86.6 | 12.8 | 0.6 |
| Kayaalti et al., 2011 (92) | Turkish | 354 | Men and women | 90.4 | 9.0 | 0.6 |
| McElroy et al., 2010 (98) | US | 142 | Black women | 97.9 | 2.1 | - |
| 149 | White women | 87.3 | 12.8 | - | ||
| Kayaalti et al., 2010 (93) | Turkish | 122 | Men and women (kidney samples) | 88.5 | 10.7 | 0.8 |
| 186 | Men and women (blood samples) | 86.0 | 13.4 | 0.6 | ||
| Kayaalti et al., 2010 (94) | Turkish | 114 | Men and women (kidney samples) | 87.7 | 11.4 | 0.9 |
| Hayashi et al., 2006 (96) | 37 | Patients with SALS | 75.7 | 24.3 | 0.0 | |
| Japanese | 206 | Control healthy men and women | 82.5 | 17.0 | 0.5 | |
Association between the rs10636 (MT2A +838G/O sinslenucleotide nolvmornhism and element concentrations in humans
| Authors and year of publication (reference No.) | Ethnicity | n | Study participants | Sample type | MT2A genotype | Findings | ||
|---|---|---|---|---|---|---|---|---|
| GG | GC | CC | ||||||
| Cd concentrations (μg/L) | ||||||||
| Adams et al., 2015 (104) | US | 321 | Men and women | Urine | (Graphical illustration) | ↓Cd in urine of C allele carriers | ||
| Chen et al, 2012 (118) | Chinese | 311 | Women exposed to Cd | Blood/ Urine | (Graphical illustration) | Trends of ↓Cd in blood of C allele carriers in highly polluted area; no difference of Cd in urine | ||
| Pb concentrations (μg/L) | ||||||||
| Yang et al., 2017 (105) | Thai | 677 | Men and women | Whole blood | 116±119 | 121±121 | 124±141 | No difference between genotypes |
| Fernandes et al, 2016(119) | Brazilian | 221 | Workers in car battery factories | Whole blood | (Graphical illustration) | C allele carriers ↓Pb in blood | ||
| Gundacker et al., 2009 (120) | Austrian | 122 | Men and women | Whole blood | 20.2 | 21.3 | 16.9 | CC genotype had ↓ Pb in blood |
| Hg concentrations (μg/Lor μg/kg*) | ||||||||
| Woods et al, 2013(116) | Portuguese | 96 | Boys of avg. age 10 years | Urine | 2.17±2.15 | 2.16±2.16§ | No difference between genotypes | |
| Wang et al., 2012 (106) | US | 464 | Men and women | Urine | 1.04 | 1.04 | 1.22 | No difference between genotypes |
| 473 | Men and women | Hair | 500* | 430* | 570* | |||
| Fe concentrations (mg/L) | ||||||||
| Giacconi et al., 2007(113) | Italian | 288 | CS patients | Plasma | 1.11±0.47 | 0.99±0.32§ | C allele carriers had ↓Fe in plasma | |
| Erythrocytes | 505±270 | 506±102§ | ||||||
| Zn concentrations (mg/L) | ||||||||
| Adams et al, 2015 (104) | US | 321 | Men and women | Urine | (Graphical illustration) | ↓Zn in urine of C allele carriers | ||
| Giacconi et al, 2007 (113) | Italian | 288 | Patients with CS | Plasma | 0.71±0.17 | 0.74±0.15§ | C allele carriers ↑Zn in erythrocytes | |
| Erythrocytes | 7.4±2.6 | 8.5±2.0§ | ||||||
| Cu concentrations (mg/L) | ||||||||
| Adams et al, 2015 (104) | US | 321 | Men and women | Urine | (Graphical illustration) | ↓Cu in urine of C allele carriers | ||
| Giacconi et al, 2007 (113) | Italian | 288 | Patients with CS | Plasma | 1.07±0.29 | l.ll±0.24§ | C allele carriers ↑Cu in erythrocytes | |
| Erythrocytes | 0.52±0.11 | 0.56±0.13§ | ||||||